A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.
By inhibiting a certain protein, the researchers were able to reduce the signals that trigger an inflammation. The study is published in Science and was done in collaboration with the University of Texas Medical Branch, Uppsala University and Stockholm University.
“We’ve developed a new drug molecule that inhibits inflammation,” says Professor Thomas Helleday, at the Department of Oncology-Pathology, Karolinska Institutet, Sweden, who co-led the study with Dr Torkild Visnes and Dr Armando Cázares-Körner. “It acts on a protein that we believe is a general mechanism for how inflammation arises in cells.”
The discovery is the result of many years of research by Thomas Helleday’s group on how DNA is repaired by the body. One of the objectives has been to fight cancer by targeting damage to the tumour cells’ DNA. Several breakthroughs have already been reported, which have led, amongst other things, to a new treatment for congenital breast and ovarian cancer using so-called PARP inhibitors, which has been available for some years.
Trials on mice
It was when developing a new molecule for inhibiting the enzyme that repairs oxygen damage to DNA that the researchers found, to their surprise, that it also dampened inflammation. It turned out that the enzyme OGG1, apart from repairing DNA, also triggers inflammation.
The inhibitor blocks the release of inflammatory proteins, such as TNF alpha. In trials on mice with acute pulmonary disease, the researchers succeeded in dampening the inflammation.
“This discovery could give rise to a new treatment for a very serious condition,” says Professor Helleday. “We’ll now be developing our OGG1 inhibitor and examining whether it can lead to new treatments for inflammatory diseases in order to cure or relieve diseases such as sepsis, COPD and severe asthma.”
The discovery was made in collaboration with Professor Istvan Boldogh from the University of Texas Medical Branch, USA.
The repair pathway on which OGG1 operates was discovered by Tomas Lindahl at Karolinska Institutet in the 1970s, an achievement that earned him the Nobel Prize in Chemistry in 2015.
Collaboration between several universities
The study was a collaboration between Karolinska Institutet, Uppsala University and Stockholm University in Sweden and the University of Texas Medical Branch, USA.
Learn more: New inflammation inhibitor discovered
The Latest on: Anti-inflammatory drug
via Google News
The Latest on: Anti-inflammatory drug
- CBD oil a curveball for drug testing on December 8, 2018 at 9:00 pm
It is said to have anti-inflammatory and anti-anxiety effects ... they had heard of some employees claiming CBD use as an excuse for a positive result on a drug test. Both said legal CBD should not tu... […]
- Anti-inflammatory drug could be used to ease untreatable high blood pressure on December 8, 2018 at 6:59 pm
Melbourne researchers have cracked a cause of untreatable high blood pressure, which could soon see the dangerous condition treated as an immune disease with drugs currently used for gout and rheumato... […]
- The Global Market for Rheumatoid Arthritis Drugs (2018-2022): Analysis by Type of Molecule, Type of RA, Region and Vendor on December 7, 2018 at 8:45 am
Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of ... […]
- Prescription drugs not being handed out 'willy-nilly', says Leinster boss Leo Cullen on December 6, 2018 at 11:56 pm
"I was never a big fan, and even to this day, I’m not a big fan of taking medication. "That’s not to say I haven’t taken an anti-inflammatory. Like, rugby as a game, it’s a physical contact sport. "Wi... […]
- 'Any time there is medication involved everyone needs to be very, very cautious' - Leo Cullen on December 6, 2018 at 5:30 pm
"I was never a big fan, and even to this day, I'm not a big fan of taking medication," Cullen began. "That's not to say I haven't taken an anti-inflammatory. Like, rugby as a game, it's a physical, co... […]
- Global Rheumatoid Arthritis Drugs Market (2018-2022): Expected to Register a CAGR of ~8% - ResearchAndMarkets.com on December 6, 2018 at 9:43 am
Unlike conventional DMARDs, such as nonsteroidal anti-inflammatory drugs (NSAIDs) that simply provide symptomatic relief, biologics are considered a more effective medication for management of rheumat... […]
- Haryana writes to DCGI to ban toxic drugs to save vultures on December 5, 2018 at 8:35 pm
CHANDIGARH: The Haryana government has written to the Drugs Controller General of India (DCGI) to ban non-steroidal anti-inflammatory drugs (NSAID) — ketoprofane and aceclofenac — as part of ... […]
- The Rheumatoid Arthritis Drugs Market will register a CAGR of close to 8% by 2022 on December 3, 2018 at 3:35 pm
Download the full report: https://www.reportbuyer.com/product/5638948 Market Overview Increasing need for affordable biologics for rheumatoid arthritis Unlike conventional DMARDs, such as nonsteroidal ... […]
- Anti-Inflammatory Therapeutics Market 2017 2021: Analysis, Size, Share, Growth, Industry Report on December 1, 2018 at 11:31 pm
About Anti-Inflammatory Therapeutics Inflammation is a part of immune response triggered against harmful stimuli, foreign objects, damaged cells, irritants, and pathogens in the body. The drugs ... […]
via Bing News